Phase 3 randomized trial of latozinemab in frontotemporal dementia due to GRN mutations.

What was studied

INFRONT-3 was a phase 3 trial of latozinemab. It tested the drug in frontotemporal dementia from GRN gene changes. People got the drug or placebo into a vein every 4 weeks for 96 weeks. The dose was 60 mg/kg. People either had symptoms or were at risk. The aim was to raise levels of progranulin, which is low in this disease. People who finished could join a 96-week open-label extension.

What they found

The drug kept progranulin levels raised in blood and spinal fluid. This was seen in people with symptoms, the main group studied. But it did not slow disease progression on clinical or biomarker measures. No safety warning signs were found.

What it means for patients

The authors say the drug raised progranulin but did not slow the illness. They call these the first phase 3 results for a trial drug in this illness. They cover both efficacy and safety.

Why it is not certain yet

The abstract gives no numbers on how much progranulin rose. It does not give results for people without symptoms. It also gives no data from the extension phase.

Source

Phase 3 randomized trial of latozinemab in frontotemporal dementia due to GRN mutations.

We restate facts from the source record in our own words. The original wording belongs to its publisher.